DNMT3A and gastric cancer: Accordingly, clinical data from TCGA database suggested that higher DNMT3a expression was correlated to shorter overall survival and post progression survival in gastric cancer patients (Figure 3B,C), strongly indicating that upregulated DNMT3a may mediate chemoresistance in gastric cancer.